This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-30 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
== External links == The Macromolecular Structure Database (MSD) at the European Bioinformatics Institute (EBI) – Serves a list of the Probable Quaternary Structure (PQS) for every protein in the Protein Data Bank (PDB). PQS server – PQS has not been updated since August 2009 PISA – The Protein Interfaces, Surfaces and Assemblies server at the MSD. EPPIC – Evolutionary Protein–Protein Interface Classification: evolutionary assessment of interfaces in crystal structures 3D complex[link removed] – Structural classification of protein complexes Proteopedia – Proteopedia Home Page The collaborative, 3D encyclopedia of proteins and other molecules. PDBWiki – PDBWiki Home Page – a website for community annotation of PDB structures. ProtCID – ProtCID—a database of similar protein–protein interfaces in crystal structures of homologous proteins.
This has been cited as an example of the importance of sympathetic influential individuals to the publication of cold fusion papers in certain journals. The decline of publications in cold fusion has been described as a "failed information epidemic". The sudden surge of supporters until roughly 50% of scientists support the theory, followed by a decline until there is only a very small number of supporters, has been described as a characteristic of pathological science. The lack of a shared set of unifying concepts and techniques has prevented the creation of a dense network of collaboration in the field; researchers perform efforts in their own and in disparate directions, making the transition to "normal" science more difficult. Cold fusion reports continued to be published in a few journals like Journal of Electroanalytical Chemistry and Il Nuovo Cimento. Some papers also appeared in Journal of Physical Chemistry, Physics Letters A, International Journal of Hydrogen Energy, and a number of Japanese and Russian journals of physics, chemistry, and engineering. Since 2005, Naturwissenschaften has published cold fusion papers; in 2009, the journal named a cold fusion researcher to its editorial board. In 2015 the Indian multidisciplinary journal Current Science published a special section devoted entirely to cold fusion related papers.
=== Viscosity === The rheology of nanocellulose dispersions has been investigated. and revealed that the storage and loss modulus were independent of the angular frequency at all nanocellulose concentrations between 0.125% to 5.9%. The storage modulus values are particularly high (104 Pa at 3% concentration) compared to results for CNCs (102 Pa at 3% concentration). There is also a strong concentration dependence as the storage modulus increases 5 orders of magnitude if the concentration is increased from 0.125% to 5.9%. Nanocellulose gels are also highly shear thinning (the viscosity is lost upon introduction of the shear forces). The shear-thinning behaviour is particularly useful in a range of different coating applications. It is pseudo-plastic and exhibits thixotropy, the property of certain gels or fluids that are thick (viscous) under normal conditions, but become less viscous when shaken or agitated. When the shearing forces are removed the gel regains much of its original state.
In his first reelection bid, Mizell defeated Democrat James G. White, 68,937 (58.1 percent) to 49,663 (41.9 percent). He was endorsed that year by Americans for Constitutional Action (ACA). Charles McManus, the ACA's president, said, "He has repeatedly stood for fiscal responsibility; firm responsible opposition to the Communists; and for law and order in our streets and institutions of learning." In a 1971 speech to Congress, Mizell voiced his support for MLB's antitrust exemption. "[T]hrough baseball, opportunities have been afforded to young men who otherwise would not have been able to fully enjoy the American dream. Baseball builds character into young men who are going to be the leaders of the future." In 1972, he trounced former Arkansas Congressman Brooks Hays, who had moved to North Carolina, 101,375 (64.8 percent) to 54,986 (35.2 percent). During this term, he was a cosponsor of House Resolution 6992, which proposed equal rights to broadcast media outlets for the chance to broadcast sporting events. In 1972, he chaired a committee that tried to set up a Billy Graham Crusade in Washington, D.C., in 1973. Mizell opposed the Appalachian Power Company's Blue Ridge Power Project, a plan to build two dams on the New River. He was concerned about the project's impact: "Changing the basis for this environmental destruction from ‘pollution‐dilution’ to ‘power crisis’ does not lessen or eliminate the environmental destruction itself...Just as much land will . . . be flooded.
spliceosome A large ribonucleoprotein complex found primarily in the nucleus of eukaryotic cells, composed of multiple small nuclear ribonucleoproteins (snRNPs) which are themselves composed of small nuclear RNAs (snRNAs) and a variety of snRNP-specific proteins. Spliceosomes assemble at the junctions between exons and introns within primary RNA transcripts and catalyze the removal of the introns and the ligation of the flanking exons in a form of post-transcriptional processing known as RNA splicing.
Sources: en.wikipedia.org
The two halves of the atom A will end up on opposite edges of the strip, over two atoms A1 and A2 of the graphene. The line from A1 to A2 will correspond to the circumference of the cylinder that went through the atom A, and will be perpendicular to the edges of the strip. In the graphene lattice, the atoms can be split into two classes, depending on the directions of their three bonds. Half the atoms have their three bonds directed the same way, and half have their three bonds rotated 180 degrees relative to the first half. The atoms A1 and A2, which correspond to the same atom A on the cylinder, must be in the same class. It follows that the circumference of the tube and the angle of the strip are not arbitrary, because they are constrained to the lengths and directions of the lines that connect pairs of graphene atoms in the same class. Let u and v be two linearly independent vectors that connect the graphene atom A1 to two of its nearest atoms with the same bond directions. These are the graphene's lattice vectors. For example, if one numbers consecutive carbons around a graphene cell with C1 to C6, then u can be the vector from C1 to C3, and v the vector from C1 to C5. Then, for any other atom A2 with same class as A1, the vector from A1 to A2 can be written as a linear combination n u + m v, where n and m are integers. And, conversely, each pair of integers (n,m) defines a possible position for A2.
== U == UbiD protein domain - ubiquitin—calmodulin ligase - UDP-3-O-N-acetylglucosamine deacetylase - UDP-4-amino-4,6-dideoxy-N-acetyl-alpha-D-glucosamine transaminase - undecaprenyl-phosphate 4-deoxy-4-formamido-L-arabinose transferase - untranslated RNA - upstream - upstream activator sequence - upstream DNA - upstream (transduction) - uracil - uracil/thymine dehydrogenase - ureidoglycolate hydrolase -
Specific terms are used to describe nerves and their actions. A nerve that supplies information to the brain from an area of the body, or controls an action of the body is said to innervate that section of the body or organ. Other terms relate to whether the nerve affects the same side ("ipsilateral") or opposite side ("contralateral") of the body, to the part of the brain that supplies it.
=== Effects on eukaryotes === Most aminoglycosides used as antibiotics are selective for the prokaryotic ribosome, binding to the eukaryotic ribosome with low affinity and largely not interfering with them. Still, some of them show significant effects on eukaryotes such as people and human cell cultures.
Sources: en.wikipedia.org
In mass spectrometry, matrix-assisted laser desorption/ionization (MALDI) is an ionization technique that uses a laser energy-absorbing matrix to create ions from large molecules with minimal fragmentation. It has been applied to the analysis of biomolecules (biopolymers such as DNA, proteins, peptides and carbohydrates) and various organic molecules (such as polymers, dendrimers and other macromolecules), which tend to be fragile and fragment when ionized by more conventional ionization methods. It is similar in character to electrospray ionization (ESI) in that both techniques are relatively soft (low fragmentation) ways of obtaining ions of large molecules in the gas phase, though MALDI typically produces far fewer multi-charged ions. MALDI methodology is a three-step process. First, the sample is mixed with a suitable matrix material and applied to a metal plate. Second, a pulsed laser irradiates the sample, triggering ablation and desorption of the sample and matrix material. Finally, the analyte molecules are ionized by being protonated or deprotonated in the hot plume of ablated gases, and then they can be accelerated into whichever mass spectrometer is used to analyse them.
In January 2026, the Moore administration reached annual pay agreements with six state employee unions, but failed to reach an agreement with AFSCME Maryland Council 3, the state's largest union of state government workers, by the December 31 deadline. Despite this, a pay increase for AFSCME-represented workers equivalent to agreements reached with several smaller unions that average 2% was included in Moore's fiscal year 2027 budget proposal.
=== International hospitals and facilities === Internationally, UPMC operates a transplant hospital in Italy (ISMETT), two hospitals and two cancer centers in Ireland, a cancer center in Rome and previously helped to establish an emergency medical system in Qatar. UPMC also implemented information technology solutions and assisting with the development of cancer centers in the United Kingdom, is providing consultation services and developing a network of co-managed hospitals in China, and, with the University of Pittsburgh School of Medicine, implemented a U.S.-style resident training program in Japan. UPMC is also a partner with the University of Pittsburgh and the governments of Italy and the region of Sicily in Fondazione Ri.Med, which is building a €210 million Biomedical Research and Biotechnology Center in Carini near Palermo. In June 2019, UPMC signed a deal with the Wanda Group to develop and operate five private hospitals in major Chinese cities. The first hospital, the Chengdu Wanda-UPMC International Hospital, is expected to open in 2022.
== Introduction == The two primary classes of therapeutics are small molecules and protein therapeutics. The design of small molecule inhibitors of protein-protein interactions (PPIs) has been impeded by issues such as the general lack of small-molecule starting points for drug design, the typical flatness of the interface, the difficulty of distinguishing real from artifactual binding, and the size and character of typical small-molecule libraries. Meanwhile, the protein therapeutics that lack these issues are bedeviled by another problem, poor cell penetration due to an insufficient ability to diffuse across the cell membrane. Additionally, proteins and peptides are often subject to proteolytic degradation in vivo or if they do enter the cell. Furthermore, small peptides (such as single alpha-helices or α-helices) can lose helicity in solution due to entropic factors, which diminishes binding affinity. α-Helices are the most common protein secondary structure and play a key role in mediating many PPIs by serving as recognition motifs. PPIs are frequently misregulated in disease, providing the long-running impetus to create alpha-helical peptides to inhibit disease-state PPIs for clinical applications, as well as for basic science applications. Introducing a synthetic brace (staple) helps to lock a peptide in a specific conformation, reducing conformational entropy. This approach can increase target affinity, increase cell penetration, and protect against proteolytic degradation.
Legal opium production is allowed under the United Nations Single Convention on Narcotic Drugs and other international drug treaties, subject to strict supervision by the law enforcement agencies of individual countries. The leading legal production method is the Robertson-Gregory process, whereby the entire poppy, excluding roots and leaves, is mashed and stewed in dilute acid solutions. The alkaloids are then recovered via acid-base extraction and purified. The exact date of its discovery is unknown, but it was described by Wurtz in his Dictionnaire de chimie pure et appliquée published in 1868. Legal opium production in India is much more traditional. As of 2008, opium was collected by farmers who were licensed to grow 0.1 hectares (0.25 acres) of opium poppies, who to maintain their licences needed to sell 56 kilograms of unadulterated raw opium paste. The price of opium paste is fixed by the government according to the quality and quantity tendered. The average is around 1500 rupees (US$29) per kilogram. Some additional money is made by drying the poppy heads and collecting poppy seeds, and a small fraction of opium beyond the quota is sometimes consumed locally or diverted to the black market. The opium paste is dried and processed into government opium and alkaloid factories before it is packed into cases of 60 kilograms for export. Purification of chemical constituents is done in India for domestic production, but typically done abroad by foreign importers.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.